Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045864 · ClinicalTrials.gov registry record · Phase 2
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
A Phase 2 study of Lymphoma, Non-Hodgkin, sponsored by Chiron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00045864 is a Phase 2 study of Lymphoma, Non-Hodgkin that has completed, run by Chiron Corporation. The trial reports 20 study locations across 11 states.
The verdict
NCT00045864, a Phase 2 study of Lymphoma, Non-Hodgkin, has completed, sponsored by Chiron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG Recombinant Human Interleukin-2 and Rituximab
Study Locations (20)
California
- Hoag Cancer Center - Newport Beach
- UC Davis Cancer Center - Sacramento
- John Wayne Cancer Institute - Santa Monica
- Stanford University Medical Center - Stanford
- California Cancer Medical Center - West Covina
Illinois
- Northwestern University, Feinberg School of Medicine - Chicago
- Rush Cancer Institute - Chicago
- Oncology Specialists, S.C. - Park Ridge
District of Columbia
- Georgetown University Medical Center, Lombardi Cancer Center - Washington D.C.
- Washington Cancer Institute - Washington D.C.
Missouri
- Kansas City Oncology and Hematology Group - Kansas City
- Arch Medical Group, LLC - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
- Our Lady of Mercy Medical Center, Comprehensive Cancer Center - The Bronx
Arizona
- ACRC/Arizona Clinical Research Center, Inc. - Tucson
Florida
- Division of Hematology/Oncology, University of Miami School of Medicine - Miami
Indiana
- Cancer Care Center - Bloomington
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045864
The ClinicalTrials.gov registry entry for NCT00045864 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Chiron Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which Recombinant Human Interleukin-2 and Rituximab is the first listed.
NCT00045864 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00045864 about?
NCT00045864 is a clinical study titled "Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.". The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
What is the current status of trial NCT00045864?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00045864 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT00045864?
The interventions under investigation include: Recombinant Human Interleukin-2 and Rituximab (DRUG).
Who is sponsoring clinical trial NCT00045864?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00045864 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.